PTC Therapeutics
PTCT
114 hedge funds and large institutions have $615M invested in PTC Therapeutics in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 38 reducing their positions, and 18 closing their positions.
98% more capital invested
Capital invested by funds: $310M → $615M (+$304M)
93% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $9.92M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
0% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 38
1% less funds holding
Funds holding: 115 → 114 (-1)
9.91% less ownership
Funds ownership: 91.23% → 81.32% (-9.9%)
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$53.2M |
| 2 |
RI
RTW Investments
New York
|
+$26.9M |
| 3 |
D.E. Shaw & Co
New York
|
+$10M |
| 4 |
Morgan Stanley
New York
|
+$6.76M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.81M |
Top Sellers
| 1 |
JGC
J. Goldman & Co
New York
|
-$16.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$10.1M |
| 3 |
Millennium Management
New York
|
-$7.36M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.1M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$6.72M |
PTCT Hedge Fund Activity: Q2 2017 in Review
114 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2017, worth a combined $615M — up 98% from $310M a quarter earlier.
Fund positioning in PTCT was balanced in Q2 2017: 18 funds opened new positions, 18 closed out, 38 added to existing stakes and 38 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $53.2M. The largest seller was J. Goldman & Co, cutting an estimated $16.8M.
- 114 institutional investors held PTC Therapeutics (PTCT) as of Q2 2017, down from 115 in Q1 2017.
- Funds reported $615M of PTC Therapeutics stock for Q2 2017, up 98% quarter-over-quarter.
- 18 funds opened new PTC Therapeutics positions in Q2 2017 and 18 closed out, a net change of 0 holders.
- The largest PTC Therapeutics buyer in Q2 2017 was Consonance Capital Management, an estimated $53.2M added.
- The largest PTC Therapeutics seller in Q2 2017 was J. Goldman & Co, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2017.